Transgenic Group (2342) · RiskRestated
Dependence on Key Individuals
First written in FY2016. 1 of 2 entries say "Restated". Latest entry: FY2017.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Risk of dependence on specific executives and specialist personnelA theme 66 companies write about · 66 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2026: 9 of 30 companies on the "Worse" side.
38 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 66 companies compared. The sentences above are computed from all 66.Full recordFilings, disclosures and news, newest first
- FY2017RestatedAnnual report
「If, for any reason, it becomes difficult for that individual to remain involved in the Company's operations, this could have a material impact on the Group's research and development activities and business strategy.」
The Company continues to identify its dependence on the individual who developed the variable gene-trap method as a risk. - FY2016First statedAnnual report
「If, for any reason, it becomes difficult for that individual to remain involved in the Company's operations, this could have a material impact on the Group's research and development activities and business strategy.」
The Company describes its dependence on a director who developed the variable gene-trap method, in terms of research and development, professional networks and credibility.